Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Current Assets (2016 - 2025)

Historic Current Assets for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $541.1 million.

  • Corcept Therapeutics' Current Assets rose 1587.91% to $541.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $541.1 million, marking a year-over-year increase of 1587.91%. This contributed to the annual value of $471.6 million for FY2024, which is 282.71% up from last year.
  • Per Corcept Therapeutics' latest filing, its Current Assets stood at $541.1 million for Q3 2025, which was up 1587.91% from $443.1 million recorded in Q2 2025.
  • Corcept Therapeutics' Current Assets' 5-year high stood at $560.8 million during Q2 2024, with a 5-year trough of $266.5 million in Q4 2021.
  • For the 5-year period, Corcept Therapeutics' Current Assets averaged around $449.0 million, with its median value being $443.1 million (2025).
  • In the last 5 years, Corcept Therapeutics' Current Assets tumbled by 4431.3% in 2021 and then soared by 8736.3% in 2022.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Current Assets stood at $266.5 million in 2021, then skyrocketed by 87.36% to $499.3 million in 2022, then decreased by 8.14% to $458.6 million in 2023, then increased by 2.83% to $471.6 million in 2024, then grew by 14.74% to $541.1 million in 2025.
  • Its last three reported values are $541.1 million in Q3 2025, $443.1 million for Q2 2025, and $438.5 million during Q1 2025.